{
    "info": {
        "nct_id": "NCT03779854",
        "official_title": "Multi-Center Phase II Randomized Controlled Trial of Na√Øve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults",
        "inclusion_criteria": "* The patient must have one of the following diagnoses and be considered to be an appropriate candidate for allogeneic HCT by the study site principal investigator (PI):\n\n  * Acute lymphoblastic leukemia (ALL) with < 5% marrow blasts.\n  * Acute myeloid leukemia (AML) with < 25% marrow blasts.\n  * Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia [ABL], ambiguous lineage [ALAL], mixed phenotype acute leukemia [MPAL], blastic plasmacytoid dendritic cell neoplasm [BPDCN], acute undifferentiated leukemia [AUL], lymphoblastic lymphoma, Burkitt leukemia/lymphoma, mast cell leukemia, chronic monocytic leukemia [CML] with blast crisis or other chronic myeloproliferative neoplasm) with < 5% marrow blasts.\n  * Myelodysplastic syndrome (MDS) with excess blasts (EB-1 and EB-2) and has received cytotoxic induction chemotherapy (excluding small molecule inhibitors and de-methylating agents)\n* Age 6 months to 26 years at the time informed consent is obtained using the Informed Consent to Participate in a Research Study form\n* Matched related donor (MRD) or matched unrelated donor (MUD) (defined as 8/8 match for human leukocyte antigen [HLA]-A, -B, -C, -DRB1).\n* Planned product type for infusion is PBSC or BM (i.e. not cord blood):\n\n  * For feasibility phase, planned product type for infusion must be PBSC.\n  * For RCT, planned product type must be PBSC or BM.\n* Karnofsky or Lansky score >= 60%.\n* Left ventricular ejection fraction (LVEF) at rest >= 40%.\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) >= 60% predicted by pulmonary function tests (PFTs)\n\n  * Patients who are unable to perform PFTs (age < 6 years or considered developmentally incapable of PFTs): oxygen saturation (by oximetry) must be >= 92% on room air.\n* Total bilirubin =< 2 x upper limit of normal (ULN) (unless value[s] > 2 x ULN are disease- or medication-related).\n\n  * If value(s) are > 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal (GI) physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.\n* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2 x ULN (unless value[s] > 2 x ULN are disease- or medication-related).\n\n  * If value(s) are > 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal GI physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.\n* Serum creatinine (SCr) within normal range for age. If SCr is outside normal range for age, creatinine clearance (CrCl) > 40 mL/min/1.73m^2 must be obtained (measured by 24-hour [hr] urine specimen or nuclear glomerular filtration rate [GFR]).\n\n  * Age (Years): Maximum SCr (mg/dL)\n  * =< 5: 0.8\n  * 6-10: 1\n  * 11-15: 1.2\n  * > 15: 1.5\n* Recipient informed consent/assent/legal guardian permission documentation must be obtained.\n* DONOR: May be related (MRD) or unrelated (MUD) to the subject.\n* DONOR: Must be matched to the subject at 8/8 HLA alleles (HLA-A, -B, -C, and -DRB1)\n* DONOR: Be >=14 years of age.\n* DONOR: Must be available to donate in the United States of America (USA) (i.e. excludes international donors).\n* DONOR: Must agree to donate BM or PBSC (i.e. agree to donate whichever product type is requested) (applicable only to the RCT phase of this study).\n* DONOR: MUDs:\n\n  * Must give informed consent according to applicable National Marrow Donor Program (NMDP) donor regulatory requirements\n  * Must meet eligibility criteria as defined by the NMDP or be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii))\n\n    * Tests must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory\n* DONOR: MRDs:\n\n  * Must be negative for human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2, hepatitis B, hepatitis C (serological and/or nucleic acid testing [NAT] and/or other approved testing)\n  * Must meet institutional donor eligibility criteria, or be ineligible with statement that the donor is a first or second degree relative (exception 21 CRF 1271.65(b)(i)).\n\n    * Tests must be performed using FDA licensed, cleared, and approved test kits in a CLIA-certified laboratory.\nHealthy volunteers allowed\nMust have minimum age of 6 Months\nMust have maximum age of 26 Years",
        "exclusion_criteria": "* Active central nervous system (CNS) disease. A patient may have a history of CNS disease; however, any CNS disease must be cleared by the end of the pre-conditioning evaluation. If CNS disease is identified on the first cerebrospinal fluid (CSF) evaluation within 30 days of the start of the preparative regimen, a repeat CSF evaluation must be performed and show no evidence of disease in order for the patient to be eligible for the protocol.\n* Patients on other experimental protocols for the prevention of GVHD.\n* Patient body weight:\n\n  * Matched related donor (MRD): > 100 kg are ineligible\n  * Matched unrelated donor (MUD): > 75 kg must be discussed with the protocol principal investigator (PI) prior to enrollment.\n* HIV-positive.\n* Uncontrolled infections must be evaluated by an infectious disease physician and considered suitable to undergo HCT by the study site PI, infectious disease physician and protocol PI. Upper respiratory tract infection (URI) does not constitute an uncontrolled infection in this context.\n* Life expectancy < 3 months from disease other than acute leukemia or myelodysplastic syndrome (MDS).\n* Significant medical condition that would make recipient unsuitable for HCT.\n* Prior allogeneic or autologous HCT.\n* Females who are pregnant or breastfeeding.\n* Patients of child bearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during study treatment and for 12 months following HCT.\n* Known hypersensitivity to tacrolimus, fludarabine, or methotrexate (MTX).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have maximum age of 26 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 26 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 26,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 6 months to 26 years at the time informed consent is obtained using the Informed Consent to Participate in a Research Study form",
            "criterions": [
                {
                    "exact_snippets": "Age 6 months to 26 years at the time informed consent is obtained",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0.5,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 26,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia [ABL], ambiguous lineage [ALAL], mixed phenotype acute leukemia [MPAL], blastic plasmacytoid dendritic cell neoplasm [BPDCN], acute undifferentiated leukemia [AUL], lymphoblastic lymphoma, Burkitt leukemia/lymphoma, mast cell leukemia, chronic monocytic leukemia [CML] with blast crisis or other chronic myeloproliferative neoplasm) with < 5% marrow blasts.",
            "criterions": [
                {
                    "exact_snippets": "Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia [ABL], ambiguous lineage [ALAL], mixed phenotype acute leukemia [MPAL], blastic plasmacytoid dendritic cell neoplasm [BPDCN], acute undifferentiated leukemia [AUL], lymphoblastic lymphoma, Burkitt leukemia/lymphoma, mast cell leukemia, chronic monocytic leukemia [CML] with blast crisis or other chronic myeloproliferative neoplasm)",
                    "criterion": "diagnosis of OAL or related neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtypes",
                            "expected_value": [
                                "acute biphenotypic leukemia (ABL)",
                                "ambiguous lineage (ALAL)",
                                "mixed phenotype acute leukemia (MPAL)",
                                "blastic plasmacytoid dendritic cell neoplasm (BPDCN)",
                                "acute undifferentiated leukemia (AUL)",
                                "lymphoblastic lymphoma",
                                "Burkitt leukemia/lymphoma",
                                "mast cell leukemia",
                                "chronic monocytic leukemia (CML) with blast crisis",
                                "other chronic myeloproliferative neoplasm"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "< 5% marrow blasts",
                    "criterion": "marrow blasts",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recipient informed consent/assent/legal guardian permission documentation must be obtained.",
            "criterions": [
                {
                    "exact_snippets": "Recipient informed consent/assent/legal guardian permission documentation must be obtained.",
                    "criterion": "informed consent/assent/legal guardian permission documentation",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) at rest >= 40%.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) at rest >= 40%",
                    "criterion": "left ventricular ejection fraction (LVEF) at rest",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age (Years): Maximum SCr (mg/dL)",
            "criterions": [
                {
                    "exact_snippets": "Age (Years): Maximum SCr (mg/dL)",
                    "criterion": "serum creatinine (SCr)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": "age-dependent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) >= 60% predicted by pulmonary function tests (PFTs)",
            "criterions": [
                {
                    "exact_snippets": "Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) >= 60% predicted by pulmonary function tests (PFTs)",
                    "criterion": "diffusing capacity of the lungs for carbon monoxide (DLCO)",
                    "requirements": [
                        {
                            "requirement_type": "correction",
                            "expected_value": "corrected for hemoglobin"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "% predicted"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky or Lansky score >= 60%.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky ... score >= 60%",
                    "criterion": "Karnofsky score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky score >= 60%",
                    "criterion": "Lansky score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myelodysplastic syndrome (MDS) with excess blasts (EB-1 and EB-2) and has received cytotoxic induction chemotherapy (excluding small molecule inhibitors and de-methylating agents)",
            "criterions": [
                {
                    "exact_snippets": "Myelodysplastic syndrome (MDS) with excess blasts (EB-1 and EB-2)",
                    "criterion": "myelodysplastic syndrome subtype",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "EB-1",
                                "EB-2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has received cytotoxic induction chemotherapy (excluding small molecule inhibitors and de-methylating agents)",
                    "criterion": "cytotoxic induction chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusions",
                            "expected_value": [
                                "small molecule inhibitors",
                                "de-methylating agents"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2 x ULN (unless value[s] > 2 x ULN are disease- or medication-related).",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... =< 2 x ULN (unless value[s] > 2 x ULN are disease- or medication-related)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... =< 2 x ULN (unless value[s] > 2 x ULN are disease- or medication-related)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If value(s) are > 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal GI physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "value(s) are > 2 x ULN and not disease- or medication related",
                    "criterion": "laboratory value(s)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "not disease- or medication related"
                        }
                    ]
                },
                {
                    "exact_snippets": "GI physician considers protocol treatment to be contraindicated for the patient",
                    "criterion": "protocol treatment contraindication (as determined by GI physician)",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: MRDs:",
            "criterions": [
                {
                    "exact_snippets": "DONOR: MRDs:",
                    "criterion": "donor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "matched related donor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: MUDs:",
            "criterions": [
                {
                    "exact_snippets": "DONOR: MUDs:",
                    "criterion": "donor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "matched unrelated donor (MUD)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* > 15: 1.5",
            "criterions": [
                {
                    "exact_snippets": "> 15: 1.5",
                    "criterion": "unknown laboratory value or measurement",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "unknown"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tests must be performed using FDA licensed, cleared, and approved test kits in a CLIA-certified laboratory.",
            "criterions": [
                {
                    "exact_snippets": "Tests must be performed using FDA licensed, cleared, and approved test kits",
                    "criterion": "test kit",
                    "requirements": [
                        {
                            "requirement_type": "FDA status",
                            "expected_value": [
                                "licensed",
                                "cleared",
                                "approved"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests must be performed ... in a CLIA-certified laboratory",
                    "criterion": "laboratory",
                    "requirements": [
                        {
                            "requirement_type": "CLIA certification",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For RCT, planned product type must be PBSC or BM.",
            "criterions": [
                {
                    "exact_snippets": "planned product type must be PBSC or BM",
                    "criterion": "planned product type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "PBSC",
                                "BM"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must meet institutional donor eligibility criteria, or be ineligible with statement that the donor is a first or second degree relative (exception 21 CRF 1271.65(b)(i)).",
            "criterions": [
                {
                    "exact_snippets": "Must meet institutional donor eligibility criteria",
                    "criterion": "institutional donor eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be ineligible with statement that the donor is a first or second degree relative",
                    "criterion": "donor relationship to recipient",
                    "requirements": [
                        {
                            "requirement_type": "relationship",
                            "expected_value": [
                                "first degree relative",
                                "second degree relative"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute myeloid leukemia (AML) with < 25% marrow blasts.",
            "criterions": [
                {
                    "exact_snippets": "Acute myeloid leukemia (AML)",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "< 25% marrow blasts",
                    "criterion": "marrow blasts",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 25,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned product type for infusion is PBSC or BM (i.e. not cord blood):",
            "criterions": [
                {
                    "exact_snippets": "Planned product type for infusion is PBSC or BM (i.e. not cord blood)",
                    "criterion": "planned product type for infusion",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "PBSC",
                                "BM"
                            ]
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "cord blood"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be negative for human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2, hepatitis B, hepatitis C (serological and/or nucleic acid testing [NAT] and/or other approved testing)",
            "criterions": [
                {
                    "exact_snippets": "Must be negative for human immunodeficiency virus (HIV)-1",
                    "criterion": "HIV-1 infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be negative for ... HIV-2",
                    "criterion": "HIV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be negative for ... human T-lymphotropic virus (HTLV)-1",
                    "criterion": "HTLV-1 infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be negative for ... HTLV-2",
                    "criterion": "HTLV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be negative for ... hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be negative for ... hepatitis C (serological and/or nucleic acid testing [NAT] and/or other approved testing)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tests must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory",
            "criterions": [
                {
                    "exact_snippets": "Tests must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits",
                    "criterion": "test kits",
                    "requirements": [
                        {
                            "requirement_type": "FDA status",
                            "expected_value": [
                                "licensed",
                                "cleared",
                                "approved"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory",
                    "criterion": "laboratory",
                    "requirements": [
                        {
                            "requirement_type": "CLIA certification",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: Must agree to donate BM or PBSC (i.e. agree to donate whichever product type is requested) (applicable only to the RCT phase of this study).",
            "criterions": [
                {
                    "exact_snippets": "Must agree to donate BM or PBSC (i.e. agree to donate whichever product type is requested)",
                    "criterion": "donation agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement to donate",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "product type flexibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: May be related (MRD) or unrelated (MUD) to the subject.",
            "criterions": [
                {
                    "exact_snippets": "DONOR: May be related (MRD) or unrelated (MUD) to the subject.",
                    "criterion": "donor relationship to subject",
                    "requirements": [
                        {
                            "requirement_type": "relationship",
                            "expected_value": [
                                "related",
                                "unrelated"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 6 Months",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 6 Months",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "Months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: Must be available to donate in the United States of America (USA) (i.e. excludes international donors).",
            "criterions": [
                {
                    "exact_snippets": "DONOR: Must be available to donate in the United States of America (USA) (i.e. excludes international donors)",
                    "criterion": "donor availability in the United States of America",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "United States of America"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 6-10: 1",
            "criterions": [
                {
                    "exact_snippets": "6-10: 1",
                    "criterion": "value in range 6 to 10",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 2 x upper limit of normal (ULN) (unless value[s] > 2 x ULN are disease- or medication-related).",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 2 x upper limit of normal (ULN) (unless value[s] > 2 x ULN are disease- or medication-related)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are unable to perform PFTs (age < 6 years or considered developmentally incapable of PFTs): oxygen saturation (by oximetry) must be >= 92% on room air.",
            "criterions": [
                {
                    "exact_snippets": "Patients who are unable to perform PFTs (age < 6 years or considered developmentally incapable of PFTs)",
                    "criterion": "ability to perform PFTs",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "age < 6 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "considered developmentally incapable of PFTs",
                    "criterion": "developmental capability to perform PFTs",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "oxygen saturation (by oximetry) must be >= 92% on room air",
                    "criterion": "oxygen saturation (by oximetry)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For feasibility phase, planned product type for infusion must be PBSC.",
            "criterions": [
                {
                    "exact_snippets": "planned product type for infusion must be PBSC",
                    "criterion": "planned product type for infusion",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "PBSC"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If value(s) are > 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal (GI) physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "value(s) are > 2 x ULN and not disease- or medication related",
                    "criterion": "laboratory value(s)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "not disease- or medication related"
                        }
                    ]
                },
                {
                    "exact_snippets": "evaluated by a gastrointestinal (GI) physician ... protocol treatment to be contraindicated ... patient will not be eligible",
                    "criterion": "GI physician evaluation",
                    "requirements": [
                        {
                            "requirement_type": "protocol treatment contraindication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient must have one of the following diagnoses and be considered to be an appropriate candidate for allogeneic HCT by the study site principal investigator (PI):",
            "criterions": [
                {
                    "exact_snippets": "one of the following diagnoses",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be considered to be an appropriate candidate for allogeneic HCT by the study site principal investigator (PI)",
                    "criterion": "appropriateness for allogeneic HCT",
                    "requirements": [
                        {
                            "requirement_type": "PI assessment",
                            "expected_value": "appropriate candidate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute lymphoblastic leukemia (ALL) with < 5% marrow blasts.",
            "criterions": [
                {
                    "exact_snippets": "Acute lymphoblastic leukemia (ALL)",
                    "criterion": "acute lymphoblastic leukemia (ALL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "< 5% marrow blasts",
                    "criterion": "marrow blasts",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must give informed consent according to applicable National Marrow Donor Program (NMDP) donor regulatory requirements",
            "criterions": [
                {
                    "exact_snippets": "Must give informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "according to applicable National Marrow Donor Program (NMDP) donor regulatory requirements",
                    "criterion": "NMDP donor regulatory requirements",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: Be >=14 years of age.",
            "criterions": [
                {
                    "exact_snippets": "Be >=14 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DONOR: Must be matched to the subject at 8/8 HLA alleles (HLA-A, -B, -C, and -DRB1)",
            "criterions": [
                {
                    "exact_snippets": "DONOR: Must be matched to the subject at 8/8 HLA alleles (HLA-A, -B, -C, and -DRB1)",
                    "criterion": "HLA allele matching between donor and subject",
                    "requirements": [
                        {
                            "requirement_type": "allele match",
                            "expected_value": {
                                "operator": "=",
                                "value": 8,
                                "unit": "out of 8"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Matched related donor (MRD) or matched unrelated donor (MUD) (defined as 8/8 match for human leukocyte antigen [HLA]-A, -B, -C, -DRB1).",
            "criterions": [
                {
                    "exact_snippets": "Matched related donor (MRD) or matched unrelated donor (MUD)",
                    "criterion": "donor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "matched related donor",
                                "matched unrelated donor"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "8/8 match for human leukocyte antigen [HLA]-A, -B, -C, -DRB1",
                    "criterion": "HLA match",
                    "requirements": [
                        {
                            "requirement_type": "allele match",
                            "expected_value": {
                                "operator": "=",
                                "value": 8,
                                "unit": "out of 8"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must meet eligibility criteria as defined by the NMDP or be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii))",
            "criterions": [
                {
                    "exact_snippets": "Must meet eligibility criteria as defined by the NMDP",
                    "criterion": "NMDP eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii))",
                    "criterion": "NMDP eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "urgent medical need statement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine (SCr) within normal range for age. If SCr is outside normal range for age, creatinine clearance (CrCl) > 40 mL/min/1.73m^2 must be obtained (measured by 24-hour [hr] urine specimen or nuclear glomerular filtration rate [GFR]).",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine (SCr) within normal range for age",
                    "criterion": "serum creatinine (SCr)",
                    "requirements": [
                        {
                            "requirement_type": "range for age",
                            "expected_value": "within normal range"
                        }
                    ]
                },
                {
                    "exact_snippets": "If SCr is outside normal range for age, creatinine clearance (CrCl) > 40 mL/min/1.73m^2",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance (CrCl) ... measured by 24-hour [hr] urine specimen or nuclear glomerular filtration rate [GFR]",
                    "criterion": "creatinine clearance (CrCl) measurement method",
                    "requirements": [
                        {
                            "requirement_type": "measurement method",
                            "expected_value": [
                                "24-hour urine specimen",
                                "nuclear glomerular filtration rate (GFR)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 11-15: 1.2",
            "criterions": [
                {
                    "exact_snippets": "11-15: 1.2",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 11,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 15,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Significant medical condition that would make recipient unsuitable for HCT.",
            "criterions": [
                {
                    "exact_snippets": "Significant medical condition that would make recipient unsuitable for HCT",
                    "criterion": "significant medical condition",
                    "requirements": [
                        {
                            "requirement_type": "impact on HCT suitability",
                            "expected_value": "would make recipient unsuitable for HCT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled infections must be evaluated by an infectious disease physician and considered suitable to undergo HCT by the study site PI, infectious disease physician and protocol PI. Upper respiratory tract infection (URI) does not constitute an uncontrolled infection in this context.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled infections must be evaluated by an infectious disease physician",
                    "criterion": "uncontrolled infection",
                    "requirements": [
                        {
                            "requirement_type": "evaluation by infectious disease physician",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "considered suitable to undergo HCT by the study site PI, infectious disease physician and protocol PI",
                    "criterion": "suitability to undergo HCT",
                    "requirements": [
                        {
                            "requirement_type": "assessment by study site PI",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment by infectious disease physician",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment by protocol PI",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Upper respiratory tract infection (URI) does not constitute an uncontrolled infection in this context",
                    "criterion": "upper respiratory tract infection (URI)",
                    "requirements": [
                        {
                            "requirement_type": "classification as uncontrolled infection",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients of child bearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during study treatment and for 12 months following HCT.",
            "criterions": [
                {
                    "exact_snippets": "Patients of child bearing age",
                    "criterion": "age group",
                    "requirements": [
                        {
                            "requirement_type": "age group",
                            "expected_value": "child bearing age"
                        }
                    ]
                },
                {
                    "exact_snippets": "who are presumed to be fertile",
                    "criterion": "fertility status",
                    "requirements": [
                        {
                            "requirement_type": "fertility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to use an effective birth control method or refrain from sexual intercourse during study treatment and for 12 months following HCT",
                    "criterion": "contraception or sexual abstinence during and after treatment",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use birth control or abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HIV-positive.",
            "criterions": [
                {
                    "exact_snippets": "HIV-positive",
                    "criterion": "HIV infection status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients on other experimental protocols for the prevention of GVHD.",
            "criterions": [
                {
                    "exact_snippets": "Patients on other experimental protocols for the prevention of GVHD",
                    "criterion": "participation in other experimental protocols for the prevention of GVHD",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Matched unrelated donor (MUD): > 75 kg must be discussed with the protocol principal investigator (PI) prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Matched unrelated donor (MUD)",
                    "criterion": "donor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "matched unrelated donor"
                        }
                    ]
                },
                {
                    "exact_snippets": "> 75 kg must be discussed with the protocol principal investigator (PI) prior to enrollment.",
                    "criterion": "donor weight",
                    "requirements": [
                        {
                            "requirement_type": "weight",
                            "expected_value": {
                                "operator": ">",
                                "value": 75,
                                "unit": "kg"
                            }
                        },
                        {
                            "requirement_type": "discussion with PI",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Matched related donor (MRD): > 100 kg are ineligible",
            "criterions": [
                {
                    "exact_snippets": "Matched related donor (MRD): > 100 kg are ineligible",
                    "criterion": "matched related donor body weight",
                    "requirements": [
                        {
                            "requirement_type": "weight",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient body weight:",
            "criterions": [
                {
                    "exact_snippets": "Patient body weight:",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic or autologous HCT.",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic or autologous HCT",
                    "criterion": "history of hematopoietic cell transplantation (HCT)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "allogeneic",
                                "autologous"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females who are pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Females who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Females who are ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system (CNS) disease. A patient may have a history of CNS disease; however, any CNS disease must be cleared by the end of the pre-conditioning evaluation. If CNS disease is identified on the first cerebrospinal fluid (CSF) evaluation within 30 days of the start of the preparative regimen, a repeat CSF evaluation must be performed and show no evidence of disease in order for the patient to be eligible for the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system (CNS) disease.",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any CNS disease must be cleared by the end of the pre-conditioning evaluation.",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "clearance by end of pre-conditioning evaluation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If CNS disease is identified on the first cerebrospinal fluid (CSF) evaluation within 30 days of the start of the preparative regimen, a repeat CSF evaluation must be performed and show no evidence of disease",
                    "criterion": "central nervous system (CNS) disease in cerebrospinal fluid (CSF)",
                    "requirements": [
                        {
                            "requirement_type": "evidence of disease on repeat CSF evaluation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy < 3 months from disease other than acute leukemia or myelodysplastic syndrome (MDS).",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy < 3 months from disease other than acute leukemia or myelodysplastic syndrome (MDS)",
                    "criterion": "life expectancy from disease other than acute leukemia or myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* =< 5: 0.8",
            "criterions": [
                {
                    "exact_snippets": "*=< 5: 0.8",
                    "criterion": "unknown parameter (symbol '*')",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Known hypersensitivity to tacrolimus, fludarabine, or methotrexate (MTX).",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to tacrolimus",
                    "criterion": "hypersensitivity to tacrolimus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to fludarabine",
                    "criterion": "hypersensitivity to fludarabine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... methotrexate (MTX)",
                    "criterion": "hypersensitivity to methotrexate",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}